Ignite Creation Date:
2025-12-25 @ 4:17 AM
Ignite Modification Date:
2025-12-26 @ 3:17 AM
Study NCT ID:
NCT01660620
Status:
COMPLETED
Last Update Posted:
2013-01-03
First Post:
2012-08-06
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Topical Betaxolol for the Prevention of Retinopathy of Prematurity
Sponsor:
Smith-Kettlewell Eye Research Institute
Organization:
Study Overview
Official Title:
Topical Betaxolol for the Prevention of Retinopathy of Prematurity
Status:
COMPLETED
Status Verified Date:
2012-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
We hypothesize that topical betaxolol will reduce the development of severe retinopathy of prematurity.
Detailed Description:
The drug is administered twice a day between 32 and 35 weeks gestational age, at a t ime when ROP is most likely to arise.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: